Genflow Biosciences plc (GENF.L) LSE

1.80

-0.025(-1.37%)

Updated at December 24 12:19PM

Currency In GBp

Genflow Biosciences plc

Address

15 Ingestre Place

London, W1F 0DU

United Kingdom of Great Britain and Northern Ireland

Phone

44 32 4774 95881

Sector

Healthcare

Industry

Biotechnology

Employees

5

First IPO Date

January 17, 2022

Key Executives

NameTitlePayYear Born
Eric Jean LeireFounder, Chief Executive Officer & Executive Director215,7931958
Cedric SzpirerHead of CMC0N/A

Description

Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.